Can Aridol give Arna Pharma and Slate Run a sharper entry into U.S. respiratory diagnostics?
Specialty pharma needs sharper U.S. routes to market. Arna Pharma and Slate Run are testing that model with Aridol and 505(b)(2) products.
Why Avenacy’s 27th injectable launch could matter more than its modest market size suggests
Injectable safety is becoming a workflow battle. Avenacy’s tranexamic acid launch tests demand for ready-to-use hospital formats.
Assertio-Garda deal analysis: what the Rolvedon-focused takeover means for specialty pharma investors
Find out why Assertio is being sold to Garda Therapeutics and what the Rolvedon-focused deal means for specialty pharma strategy.
Lupin closes VISUfarma deal, but can branded ophthalmology drive the next phase of growth?
Lupin has completed its VISUfarma acquisition. Read what the deal changes for European ophthalmology, specialty pharma growth, and execution risk.